Phase I, multicenter, open-label study of intravenous VCN-01 oncolytic adenovirus with or without nab-paclitaxel plus gemcitabine in patients with advanced solid tumors

BACKGROUND: VCN-01 is an oncolytic adenovirus (Ad5 based) designed to replicate in cancer cells with dysfunctional RB1 pathway, express hyaluronidase to enhance virus intratumoral spread and facilitate chemotherapy and immune cells extravasation into the tumor. This phase I clinical trial was aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Garcia-Carbonero, Rocio, Bazan-Peregrino, Miriam, Gil-Martín, Marta, Álvarez, Rafael, Macarulla, Teresa, Riesco-Martinez, Maria C, Verdaguer, Helena, Guillén-Ponce, Carmen, Farrera-Sal, Martí, Moreno, Rafael, Mato-Berciano, Ana, Maliandi, Maria Victoria, Torres-Manjon, Silvia, Costa, Marcel, del Pozo, Natalia, Martínez de Villarreal, Jaime, Real, Francisco X, Vidal, Noemí, Capella, Gabriel, Alemany, Ramon, Blasi, Emma, Blasco, Carmen, Cascalló, Manel, Salazar, Ramon
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Oncolytic and Local Immunotherapy
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961117/
https://www.ncbi.nlm.nih.gov/pubmed/35338084
http://dx.doi.org/10.1136/jitc-2021-003255

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8961117/
https://www.ncbi.nlm.nih.gov/pubmed/35338084
http://dx.doi.org/10.1136/jitc-2021-003255

Ejemplares similares